As animal health innovation accelerates, understanding how new technologies translate into real-world veterinary practice is critical. Oli Viner shares how Hello Vet integrates data, technology, and a transparent care model to support clinical decision-making and strengthen trust between vets, clients, and patients. This session offers a practical perspective on what innovators and partners should consider when designing solutions for adoption at the point of care.
Candise Goodwin is a recognized leader in the pet industry, with over 15 years of experience helping companies navigate market complexity, scale solutions, and deliver measurable impact. Her background spans pivotal roles at industry leaders including Merck Animal Health, Vets First Choice, VIP Petcare/PETIQ, and Petco, where she led major digital transformations and launched numerous high-profile, industry-changing growth initiatives.
Candise has dedicated her career to understanding the challenges and opportunities within the pet industry. She has worked closely with retailers, veterinary groups, pet technology companies, product and service providers, and pharmacies - developing a holistic, customer-centric viewpoint of the industry's unique ecosystem along the way.
Today, Candise extends her expertise to clients seeking to navigate the complexities of the market. Her firm, Outlier Advisors, provides strategic consulting services that reflect her distinctive blend of innovative thinking, deep industry knowledge, and ability to spot emerging trends. Outlier Advisors partners with industry leaders, investors, and startups to develop actionable strategies that meet the demands of an evolving pet landscape.
Candise is also a sought-after speaker, advisor, author, and mentor, known for sharing rare and multifaceted insights and practical strategies with fellow Outliers.
Bringing the world’s first insect vaccine from discovery to commercial reality marks a defining milestone for Dalan Animal Health. Annette Kleiser, CEO, shares how Dalan is now applying its innate immunity platform to aquaculture, advancing proof-of-concept in shrimp, and exploring broader species application.
Approval alone doesn’t guarantee commercial success. Robert Jordan shares how Vetirus Pharmaceuticals combines in-house regulatory expertise with early manufacturing planning, ensuring supply, shortening timelines to revenue, and enabling global expansion.
Scaling beyond limited early-stage momentum often calls for a disciplined corporate turnaround strategy. Jake Burlet outlines the practical steps CanBiocin took to shift from grant-to-grant R&D survival to a profitable growing enterprise through securing strategic investment.
Commercialising a new category of care requires more than product innovation. Rebecca Windsor, Director of Veterinary Affairs at Gallant, shares how education and developing trusted continuing education platforms have been central to preparing veterinarians for the clinical adoption of regenerative medicine.
